Literature DB >> 2213568

Aging alters verapamil elimination and dynamics: single dose and steady-state responses.

J B Schwartz1.   

Abstract

Verapamil elimination kinetics and pharmacodynamic effects were studied in 29 healthy individuals (23-81 years of age) after single i.v. doses (0.15-0.22 mg/kg) and during infusions to reach stable plasma verapamil concentrations of 28 +/- 11, 57 +/- 19 and 112 +/- 26 ng/ml (mean +/- S.D.). Aging prolonged verapamil elimination (P less than .008): elimination half-life of 218 +/- 91 min in young (ages 20-39), 280 +/- 78 min in middle-aged (40-59) and 288 +/- 73 min in elderly (greater than 60). After single verapamil doses. 1) heart rate increased with lesser increases in elderly subjects; 2) blood pressure decreased (P = .006) with greater decreases in elderly subjects; 3) spontaneous P-R intervals increased with lesser increases in elderly subjects but, 4) atrioventricular conduction times increased during transesophageal pacing without detectable age differences in responses. During steady-state infusions, 1) heart rate during sinus rhythm was unchanged but atrioventricular dissociation with junctional rhythms developed in elderly subjects (3/9); 2) blood pressure decreased with greater decreases in the elderly; 3) spontaneous P-R intervals increased with lesser increases in the elderly but no age differences in paced P-R interval changes were detected at equivalent verapamil concentrations; 4) heart rate variation (during sinus rhythm) decreased in an age-independent manner as measured by decreases in the S.D. of R-R intervals and decreased power spectral content with greatest changes seen in high frequency (respiratory) content; and 5) heart rate and blood pressure responses to cold pressor and handgrip testing were not attenuated by verapamil. In conclusion, aging prolongs verapamil elimination and alters dynamic responses to verapamil with greater sinus node depression and hypotensive effects in elderly vs. younger subjects. Although less spontaneous P-R interval prolongation was seen on ECG of the elderly vs. young, underlying atrioventricular conduction was prolonged by verapamil independent of age as shown by results when pacing was used to eliminate frequency-dependent effects caused by differing heart rate responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213568

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Polysomnography underestimates altered cardiac autonomic control in patients with obstructive sleep apnea.

Authors:  C Jilek; J Gebauer; F Muders; M Arzt; G Riegger; M Pfeifer; R Wensel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-03

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

Authors:  M F Fromm; K Dilger; D Busse; H K Kroemer; M Eichelbaum; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 6.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 7.  Cardiovascular drug therapy in the elderly: theoretical and practical considerations.

Authors:  Bradley R Williams; Jiwon Kim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

9.  Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.

Authors:  S K Gupta; L Atkinson; T Tu; J A Longstreth
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.